Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from MAIA Biotechnology, Inc. ( (MAIA) ).
On October 13, 2025, MAIA Biotechnology, Inc. announced a Securities Purchase Agreement with accredited investors for a private placement of 603,769 shares of common stock and warrants, raising approximately $736,600. The proceeds will be used to fund the initial costs of Step 1 of Part C of the Phase II trial THIO-101 and for working capital, with the private placement expected to close on October 15, 2025.
The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.
Spark’s Take on MAIA Stock
According to Spark, TipRanks’ AI Analyst, MAIA is a Neutral.
MAIA Biotechnology presents a mixed outlook. The company’s financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.
To see Spark’s full report on MAIA stock, click here.
More about MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. The company’s lead program, ateganosine (THIO), is a potential first-in-class cancer telomere targeting agent in clinical development for treating non-small cell lung cancer (NSCLC) patients with telomerase-positive cancer cells.
Average Trading Volume: 488,274
Technical Sentiment Signal: Sell
Current Market Cap: $50.15M
See more data about MAIA stock on TipRanks’ Stock Analysis page.